Among all the peptides that have found their way into skincare aisles, GHK-Cu is one of the oldest and most scientifically grounded. It is a glycyl-histidyl-lysine tripeptide that binds a copper(II) ion, and it has been studied for its role in wound healing, collagen synthesis, and tissue repair for over four decades. It is also, predictably, found in ampoules and vials on grey-market peptide sites — an injectable use that has essentially no regulatory backing.
This guide separates the parts of GHK-Cu that are well supported (topical cosmetic effects, copper trafficking biology, wound healing in cell culture) from the parts that are mostly marketing (systemic injectable anti-aging benefits).
The sequence and the metal
GHK is short for glycine-histidine-lysine, written in one-letter code as:
- GHK — just three residues, with an N-terminal glycine, a central histidine, and a C-terminal lysine.
What makes GHK interesting is not the peptide sequence in isolation — three residues is a tiny scaffold — but the metal-binding site it creates. The histidine imidazole ring, the N-terminal free amine, and neighboring donor atoms form a coordination pocket that binds copper(II) with reasonable affinity at physiological pH. The resulting GHK-Cu complex is the form that most of the bioactivity literature refers to.
Copper is a bioactive transition metal. It is an essential cofactor for enzymes including lysyl oxidase (involved in collagen and elastin crosslinking), copper-zinc superoxide dismutase (an antioxidant enzyme), and several cytochromes. A peptide that can carry copper in a bioavailable form therefore sits at the intersection of peptide chemistry and trace-metal biology — more interesting than it first appears.
You can see the GHK-Cu tripeptide sequence, residue categories, and property predictions in the GHK-Cu workspace. Bear in mind: a two-dimensional sequence view does not visualize the metal coordination geometry — that requires explicit ligand modeling, which sits outside the scope of a peptide playground.
Origin: a fragment with a story
The GHK tripeptide was initially characterized in the 1970s as a circulating growth-promoting factor in human plasma, active in hepatocyte culture. Subsequent work showed it was likely released as a proteolytic fragment from larger plasma proteins, most notably alpha-2-macroglobulin, during tissue injury and inflammation.
A frequently cited observation is that GHK plasma concentration declines substantially between young adulthood and older age, which led to the hypothesis that restoring GHK could partially offset age-related losses of tissue regenerative capacity. This framing became the scientific backdrop for its cosmetic development — and, separately, for more speculative claims.
Wound healing and collagen
Most of the compelling preclinical evidence for GHK-Cu sits in the wound-healing and dermal-remodeling arena. Several consistent themes emerge from the literature:
Collagen and glycosaminoglycan synthesis
Fibroblast cultures exposed to GHK-Cu show increased synthesis of collagen and glycosaminoglycans — the two main structural elements of the dermal extracellular matrix. Copper delivery to lysyl oxidase, which catalyzes collagen crosslinking, is one plausible mechanism, though multiple pathways likely contribute.
Matrix remodeling balance
GHK-Cu appears to modulate the balance of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), which together control extracellular matrix turnover. In wound-healing contexts, that balance matters more than either synthesis or breakdown alone — tissue has to remodel in a coordinated way.
Anti-inflammatory signaling
GHK-Cu has been reported to blunt some inflammatory cytokine responses in cell models and to reduce oxidative stress markers — effects that are consistent with copper-dependent antioxidant biology and that can plausibly contribute to better wound outcomes in a complex real-world context.
Angiogenesis
Small capillary-network formation in culture is enhanced in some GHK-Cu experiments, consistent with pro-healing behavior. As with BPC-157, translating cell-culture angiogenesis into meaningful clinical wound outcomes requires more than a single in vitro readout.
Cosmetic use: where the science meets the shelf
Because of its dermal-remodeling profile and its relatively safe topical use history, GHK-Cu and related copper peptide complexes are allowed ingredients in cosmetic products in major markets. They commonly appear under INCI names such as “copper tripeptide-1” in serums, creams, and post-procedure products.
Clinical and imaging studies of topical GHK-Cu formulations have reported improvements in fine lines, skin firmness, and elasticity in older skin, particularly with sustained use. The effect sizes are generally modest — these are cosmetic improvements, not pharmacological remodeling — but they are real enough to have kept GHK-Cu in the active-ingredient rotation for decades.
The Peptide Lab GHK-Cu cosmetic workspace separates the cosmetic context from the more speculative injectable framing. The peptide is the same; the context and evidence base are not.
The injectable grey market
A separate and very different conversation is happening around injectable GHK-Cu, sold online as a “research chemical” peptide. Users describe it in the context of hair regrowth, systemic anti-aging, joint repair, and other ambitious claims.
None of this prevents responsible research into whether certain injectable or formulated copper-peptide systems could ever be developed into approved therapies. It just means that the current online market is not such a development effort.
Age-related decline and the aspirational story
The observation that plasma GHK concentrations drop with age is often cited as a rationale for GHK-Cu supplementation. It is intriguing as a hypothesis generator. It is also a common pattern in aging biology: the correlation between a declining factor and age is not the same as a demonstration that restoring that factor reverses age-related phenotypes.
Well-controlled clinical trials of systemic GHK-Cu administration in humans do not really exist at the rigor level required to back strong longevity claims. The topical cosmetic literature is the most defensible position for now.
How to explore GHK-Cu responsibly
Good questions to ask when looking at any copper-peptide product:
- Is it topical or injectable? Topical cosmetic products sit in a mature regulatory lane. Injectable grey-market products do not.
- What does the peptide actually do? Copper trafficking and wound-healing signaling are real. Systemic anti-aging miracle claims are not.
- Is the evidence preclinical, human topical, or human systemic? These are three very different categories and should be weighted accordingly.
- What is the copper species? GHK without copper and GHK-Cu are different entities; the coordinated metal is central to much of the biology.
Explore in Peptide Lab
For the sequence-level side of GHK-Cu, Peptide Lab has two workspaces:
Both let you view the tripeptide sequence, residue categories, and property predictions. They are an educational starting point, not a recommendation to use any copper-peptide product.